COCRYSTAL PHARMA, INC. (COCP) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
14/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCOCP / S&P 3.96% / 15.20% |
LoseCOCP / S&P COCP unavailable / 15.00% |
LoseCOCP / S&P -38.71% / 50.40% |
| 2026-Q11/3 |
WinCOCP / S&P 3.06% / -4.33% |
LoseCOCP / S&P COCP unavailable / 11.30% |
LoseCOCP / S&P -53.50% / 27.70% |
| 2025-Q40/3 |
LoseCOCP / S&P -21.60% / 2.65% |
LoseCOCP / S&P COCP unavailable / 9.00% |
LoseCOCP / S&P -54.34% / 13.40% |
| 2025-Q30/3 |
LoseCOCP / S&P -16.11% / 8.12% |
LoseCOCP / S&P COCP unavailable / 4.61% |
LoseCOCP / S&P -49.19% / 13.45% |
| 2025-Q20/3 |
LoseCOCP / S&P 4.93% / 10.94% |
LoseCOCP / S&P COCP unavailable / 4.83% |
LoseCOCP / S&P -29.94% / 10.63% |
| 2025-Q10/3 |
LoseCOCP / S&P -29.70% / -4.27% |
LoseCOCP / S&P COCP unavailable / 4.98% |
LoseCOCP / S&P -4.85% / 10.57% |
| 2024-Q41/3 |
WinCOCP / S&P 14.77% / 2.41% |
LoseCOCP / S&P COCP unavailable / 5.25% |
LoseCOCP / S&P -8.95% / 6.15% |
| 2024-Q30/3 |
LoseCOCP / S&P -24.46% / 5.89% |
LoseCOCP / S&P COCP unavailable / 5.89% |
LoseCOCP / S&P -7.50% / 6.11% |
| 2024-Q21/3 |
WinCOCP / S&P 66.43% / 4.28% |
LoseCOCP / S&P COCP unavailable / 5.38% |
LoseCOCP / S&P -22.71% / 5.12% |
| 2024-Q10/3 |
LoseCOCP / S&P -18.60% / 10.56% |
LoseCOCP / S&P COCP unavailable / 5.71% |
LoseCOCP / S&P -66.19% / 5.59% |
| 2023-Q40/3 |
LoseCOCP / S&P -8.02% / 11.69% |
LoseCOCP / S&P COCP unavailable / 6.81% |
LoseCOCP / S&P COCP unavailable / 7.78% |
| 2023-Q30/3 |
LoseCOCP / S&P -21.76% / -3.27% |
LoseCOCP / S&P COCP unavailable / 7.52% |
LoseCOCP / S&P COCP unavailable / -5.03% |
| 2023-Q21/3 |
WinCOCP / S&P 20.10% / 8.74% |
LoseCOCP / S&P COCP unavailable / 9.50% |
LoseCOCP / S&P COCP unavailable / -8.57% |
| 2023-Q10/3 |
LoseCOCP / S&P 2.05% / 7.50% |
LoseCOCP / S&P COCP unavailable / 10.77% |
LoseCOCP / S&P COCP unavailable / -15.69% |
| 2022-Q40/3 |
LoseCOCP / S&P -43.97% / 7.56% |
LoseCOCP / S&P COCP unavailable / 11.88% |
LoseCOCP / S&P COCP unavailable / -17.99% |
| 2022-Q30/3 |
LoseCOCP / S&P -29.27% / -4.88% |
LoseCOCP / S&P COCP unavailable / 13.47% |
LoseCOCP / S&P COCP unavailable / -1.41% |
| 2022-Q20/3 |
LoseCOCP / S&P -25.45% / -16.10% |
LoseCOCP / S&P COCP unavailable / 13.71% |
LoseCOCP / S&P COCP unavailable / 11.04% |
| 2022-Q10/3 |
LoseCOCP / S&P -15.38% / -4.60% |
LoseCOCP / S&P COCP unavailable / 15.97% |
LoseCOCP / S&P COCP unavailable / 42.23% |
| 2021-Q40/3 |
LoseCOCP / S&P -38.10% / 11.03% |
LoseCOCP / S&P COCP unavailable / 15.00% |
LoseCOCP / S&P COCP unavailable / 96.40% |
| 2021-Q30/3 |
LoseCOCP / S&P -16.00% / 0.58% |
LoseCOCP / S&P COCP unavailable / 10.77% |
LoseCOCP / S&P COCP unavailable / 69.42% |
| 2021-Q20/3 |
LoseCOCP / S&P -10.07% / 8.55% |
LoseCOCP / S&P COCP unavailable / 6.58% |
LoseCOCP / S&P COCP unavailable / 51.81% |
| 2021-Q10/3 |
LoseCOCP / S&P 2.21% / 6.17% |
LoseCOCP / S&P COCP unavailable / -1.06% |
LoseCOCP / S&P COCP unavailable / 7.39% |
| 2020-Q41/3 |
WinCOCP / S&P 46.24% / 12.15% |
LoseCOCP / S&P -69.32% / -3.72% |
LoseCOCP / S&P COCP unavailable / -33.42% |
| 2020-Q30/3 |
LoseCOCP / S&P -38.82% / 8.93% |
LoseCOCP / S&P COCP unavailable / -2.04% |
LoseCOCP / S&P COCP unavailable / -27.10% |
| 2020-Q21/3 |
WinCOCP / S&P 114.08% / 20.54% |
LoseCOCP / S&P COCP unavailable / -0.46% |
LoseCOCP / S&P COCP unavailable / -27.11% |
| 2020-Q11/3 |
WinCOCP / S&P 42.00% / -19.60% |
LoseCOCP / S&P COCP unavailable / 3.47% |
LoseCOCP / S&P COCP unavailable / -14.75% |
| 2019-Q40/3 |
LoseCOCP / S&P -75.61% / 9.07% |
LoseCOCP / S&P COCP unavailable / 5.36% |
LoseCOCP / S&P COCP unavailable / 2.99% |
| 2019-Q30/3 |
LoseCOCP / S&P -12.77% / 1.70% |
LoseCOCP / S&P COCP unavailable / 5.02% |
LoseCOCP / S&P COCP unavailable / 0.21% |
| 2019-Q20/3 |
LoseCOCP / S&P -13.92% / 4.30% |
LoseCOCP / S&P COCP unavailable / 6.64% |
LoseCOCP / S&P COCP unavailable / 8.65% |
| 2019-Q10/3 |
LoseCOCP / S&P -24.17% / 13.65% |
LoseCOCP / S&P COCP unavailable / 8.12% |
LoseCOCP / S&P COCP unavailable / 14.29% |
| 2018-Q41/3 |
WinCOCP / S&P 44.00% / -13.52% |
LoseCOCP / S&P COCP unavailable / 9.05% |
LoseCOCP / S&P COCP unavailable / 18.23% |
| 2018-Q30/3 |
LoseCOCP / S&P -31.69% / 7.71% |
LoseCOCP / S&P COCP unavailable / 10.21% |
LoseCOCP / S&P -101.15% / 19.06% |
| 2018-Q20/3 |
LoseCOCP / S&P -38.49% / 3.43% |
LoseCOCP / S&P COCP unavailable / 9.03% |
LoseCOCP / S&P -102.87% / 14.46% |
| 2018-Q10/3 |
LoseCOCP / S&P -0.83% / -0.76% |
LoseCOCP / S&P COCP unavailable / 7.68% |
LoseCOCP / S&P -101.77% / 12.46% |
| 2017-Q40/3 |
LoseCOCP / S&P -25.93% / 6.64% |
LoseCOCP / S&P COCP unavailable / 7.03% |
LoseCOCP / S&P -100.30% / 13.82% |
| 2017-Q32/3 |
WinCOCP / S&P 22.73% / 4.48% |
LoseCOCP / S&P COCP unavailable / 5.68% |
WinCOCP / S&P 46.22% / 17.57% |
| 2017-Q21/3 |
LoseCOCP / S&P -18.52% / 3.09% |
LoseCOCP / S&P COCP unavailable / 4.83% |
WinCOCP / S&P 45.61% / 17.74% |
| 2017-Q11/3 |
LoseCOCP / S&P -30.77% / 6.07% |
LoseCOCP / S&P COCP unavailable / 3.67% |
WinCOCP / S&P 41.25% / 13.32% |
| 2016-Q41/3 |
LoseCOCP / S&P -20.41% / 3.82% |
LoseCOCP / S&P COCP unavailable / 2.09% |
WinCOCP / S&P 35.39% / 7.05% |
| 2016-Q31/3 |
LoseCOCP / S&P 2.08% / 3.85% |
LoseCOCP / S&P COCP unavailable / 0.20% |
WinCOCP / S&P 2875.00% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | COCP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -24.00% | 20.78% |
| Annualized return | -24.00% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | COCP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.74% | 83.14% |
| Annualized return | -39.27% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | COCP total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.21% | 319.30% |
| Annualized return | -38.36% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |